Clinical trialNCT01089101Active, not recruitingPhase 1/PHASE2Interventional

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

SponsorNational Cancer Institute (NCI)Enrollment217Low Grade GliomaRecurrent Childhood Pilocytic AstrocytomaRecurrent Neurofibromatosis Type 1Recurrent Visual Pathway GliomaRefractory Neurofibromatosis Type 1Refractory Visual Pathway Glioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jason R Fangusaro
Pediatric Brain Tumor Consortium
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Lucile Packard Children'S Hospital Stanford University
Palo Alto, California, United States
Ucsf Medical Center-Mount Zion
San Francisco, California, United States
Ucsf Medical Center-Parnassus
San Francisco, California, United States
Children'S Hospital Colorado
Aurora, Colorado, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Children'S Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia, United States
Children'S Memorial Outpatient Center in Lincoln Park
Chicago, Illinois, United States
Lurie Children'S Hospital-Chicago
Chicago, Illinois, United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Children'S Hospital of Pittsburgh of Upmc
Pittsburgh, Pennsylvania, United States
Saint Jude Children'S Research Hospital
Memphis, Tennessee, United States
Baylor College of Medicine/dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
Texas Children'S Hospital
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Selumetinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Jul 2010
Primary completion: 17 Jan 2026
Completion: 18 Mar 2027
Last update posted: 13 May 2026
Registered enrollment: 217
Registry id: NCT01089101

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.